Testosterone deficiency at the crossroads of cardiometabolic complications in CKD

American Journal of Kidney Diseases

Volumn 64, Issue 3, 2014, Pages 322-325

  Carrero, Juan Jesús ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GONADOTROPIN; TESTOSTERONE;

ADVERSE OUTCOME; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; GONADOTROPIN RELEASE; HUMAN; HYPOGONADISM; KIDNEY FUNCTION; METABOLIC DISORDER; REVIEW; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; TREATMENT INDICATION; VULNERABLE POPULATION;

HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC; TESTOSTERONE;

EID: 84907346052     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.06.002     Document Type: Editorial

References (36)

1. S. Ros, and J.J. Carrero Endocrine alterations and cardiovascular risk in CKD: is there a link? Nefrologia 33 2 2013 181 187
2. K.K. Khurana, S.D. Navaneethan, S. Arrigain, J.D. Schold, J.V. Nally Jr., and D.A. Shoskes Serum testosterone levels and mortality in men with CKD stages 3-4 Am J Kidney Dis 64 3 2014 367 374
3. J.J. Carrero, and P. Stenvinkel The vulnerable man: impact of testosterone deficiency on the uraemic phenotype Nephrol Dial Transplant 27 11 2012 4030 4041
4. Dousdampanis P, Trigka K, Fourtounas C, Bargman JM. Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease [published online ahead of print September 30, 2013]. Ther Apher Dial. http://dx.doi.org/10.1111/1744-9987.12101.
5. P. Iglesias, J.J. Carrero, and J.J. Diez Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options J Nephrol 25 1 2012 31 42
6. J.J. Carrero, J. Kyriazis, and A. Sonmez et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD Clin J Am Soc Nephrol 7 2 2012 207 215
7. M.I. Yilmaz, A. Sonmez, and A.R. Qureshi et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease Clin J Am Soc Nephrol 6 7 2011 1617 1625
8. A.K. Bello, P. Stenvinkel, and M. Lin et al. Serum testosterone levels and clinical outcomes in male hemodialysis patients Am J Kidney Dis 63 2 2014 268 275
9. J.J. Carrero, A.R. Qureshi, and A. Nakashima et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease Nephrol Dial Transplant 26 1 2011 184 190
10. S. Cigarran, M. Pousa, and M.J. Castro et al. Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease J Ren Nutr 23 5 2013 e89 e95
11. O. Gungor, F. Kircelli, and J.J. Carrero et al. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging? Clin J Am Soc Nephrol 5 11 2010 2018 2023
12. J.J. Carrero, P. Barany, and M.I. Yilmaz et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease Nephrol Dial Transplant 27 2 2012 709 715
13. Ekart R, Taskovska M, Hojs N, Bevc S, Hojs R. Testosterone and hemoglobin in hemodialysis male and female patients [published online ahead of print November 21, 2013]. Artif Organs. http://dx.doi.org/10.1111/aor.12218.
14. J. Kyriazis, I. Tzanakis, and K. Stylianou et al. Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients Nephrol Dial Transplant 26 9 2011 2971 2977
15. G. Kojo, T. Yoshida, and S. Ohkawa et al. Association of serum total testosterone concentration with skeletal muscle mass in men under hemodialysis Int Urol Nephrol 46 5 2014 985 991
16. J.J. Carrero, A.R. Qureshi, and P. Parini et al. Low serum testosterone increases mortality risk among male dialysis patients J Am Soc Nephrol 20 3 2009 613 620
17. Shoskes DA, Kerr H, Askar M, Goldfarb DA, Schold J. Low testosterone at time of transplant is independently associated with poor patient and graft survival in male renal transplant recipients [published online ahead of print April 1, 2014]. J Urol. http://dx.doi.org/10.1016/j.juro.2014.03.102.
18. B. Afsar Relationship between total testosterone, cognitive function, depressive behavior, and sleep quality in chronic kidney disease patients not on dialysis Clin Exp Nephrol 17 1 2013 59 65
19. R. Haring, M. Nauck, and H. Volzke et al. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy Am J Nephrol 33 3 2011 209 217
20. S. Bhasin, G.R. Cunningham, and F.J. Hayes et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 91 6 2006 1995 2010
21. N. Shiraki, A. Nakashima, and S. Doi et al. Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis Clin Exp Nephrol 18 3 2014 499 506
22. F. Lapi, L. Azoulay, M.T. Niazi, H. Yin, S. Benayoun, and S. Suissa Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer JAMA 310 3 2013 289 296
23. I.G. Lawrence, D.E. Price, T.A. Howlett, K.P. Harris, J. Feehally, and J. Walls Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescence therapy Am J Kidney Dis 31 2 1998 313 319
24. W.J. Gaughan, K.A. Liss, and S.R. Dunn et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients Am J Kidney Dis 30 4 1997 495 500
25. S.H. Ballal, D.T. Domoto, D.C. Polack, P. Marciulonis, and K.J. Martin Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease Am J Kidney Dis 17 1 1991 29 33
26. A.T. Brockenbrough, M.O. Dittrich, S.T. Page, T. Smith, J.C. Stivelman, and W.J. Bremner Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease Am J Kidney Dis 47 2 2006 251 262
27. J.J. Carrero, P. Stenvinkel, and L. Cuppari et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM) J Ren Nutr 23 2 2013 77 90
28. P. Aramwit, N. Kobpipat, B. Satirapoj, J.D. Kopple, and O. Supasyndh Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial Clin Nephrol 71 4 2009 413 422
29. O. Supasyndh, B. Satirapoj, and P. Aramwit et al. Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients Clin J Am Soc Nephrol 8 2 2013 271 279
30. K.L. Johansen, P.L. Painter, G.K. Sakkas, P. Gordon, J. Doyle, and T. Shubert Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial J Am Soc Nephrol 17 8 2006 2307 2314
31. K.L. Johansen, K. Mulligan, and M. Schambelan Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial JAMA 281 14 1999 1275 1281
32. M.M. Fernandez-Balsells, M.H. Murad, and M. Lane et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis J Clin Endocrinol Metab 95 6 2010 2560 2575
33. R. Vigen, C.I. O'Donnell, and A.E. Baron et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels JAMA 310 17 2013 1829 1836
34. W.D. Finkle, S. Greenland, and G.K. Ridgeway et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men PLoS One 9 1 2014 e85805
35. European Medicines Agency. Testosterone-containing medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/ Testosterone-containing-medicines/human-referral-prac-000037.jsp&mid= WC0b01ac05805c516f. Accessed June 11, 2014.
36. US Food and Drug Administration. FDA Drug Safety Communication: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm. Accessed June 11, 2014.